Skip to content

Studying the effect of hydroalcoholic extract of fennel plant on anti-mullerian hormone (AMH) in infertile women

Investigating the effect of hydroalcoholic extract of fennel plant on anti-müllerian hormone (AMH) in infertile women referred to the infertility clinic of Jalil Hospital: An interventional study of the before and after type

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20250223064826N1
Enrollment
24
Registered
2025-04-27
Start date
2025-04-07
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertile women aged 15 to 45 with AMH levels <1.1 ng/ml. Female infertility associated with anovulation

Interventions

Eligible infertile women with AMH levels below 1 ng/ml undergo initial testing. Within two weeks of the first test, they begin taking fennel powder extract capsules produced by Paleshkhaneh Giah Kala.

Sponsors

Yasouj University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
15 Years to 45 Years

Inclusion criteria

Inclusion criteria: The inclusion criteria for the study are female patients aged 15 to 45 years who undergo AMH testing before and after treatment with fennel. Fennel extract consumption begins within two weeks after the initial AMH test, and the second AMH test is performed during the follicular phase of the menstrual cycle within two months after starting fennel extract intake. The AMH level is evaluated to assess the effect of fennel extract over a minimum period of two months (500 mg daily), based on the criteria of previous studies. A diminished ovarian reserve is defined as an AMH level of less than 1.1 ng/mL.

Exclusion criteria

Exclusion criteria: Patients with primary ovarian failure. Patients who have used contraceptive pills for at least four weeks prior to the study. Patients undergoing hormone replacement therapy, cancer treatment, or gonadotropin therapy. Patients with polycystic ovary syndrome (PCOS) Patients undergoing hormonal treatments and fertility therapy Patients with endometriosis. Patients with a history of ovarian surgery. Pregnant women.

Design outcomes

Primary

MeasureTime frame
AMH. Timepoint: Se realiza una prueba de hormona antimulleriana antes y después del tratamiento con extracto hidroetanólico de hinojo. Method of measurement: Los niveles séricos de AMH se medirán mediante electroquimioluminiscencia (ECL) utilizando el analizador Cobas e 411 (Roche, Indianápolis, IN) en una muestra de sangre en ayunas.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZohreh Gorjizadeh Abdehgah

Yasouj University of Medical Sciences

rahmi.karaji@gmail.com+98 74 3323 3859

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026